Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Appl Radiat Isot ; 184: 110157, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1787999

ABSTRACT

According to the National Institute of Public Health, prostate cancer (PCa) is the leading cause of cancer death in Mexican men, highly associated with aggressiveness, resistance to treatment, and metastatic spread (Bharti et al., 2019) mediated by activation of the hypoxia-inducible factor 1 (HIF-1α). The objective of the present study was to evaluate the participation of HIF-1α activation in the radiobiological response of the human prostate adenocarcinoma cell line LNCaP, describing the phenomena with a mathematical model. Four groups were formed under different exposure conditions, including hypoxic cells treated with CoCl2 (300 µM for 22 h) with or without hypoxia-inducible factor inhibitor (150 nM chetomin for 4 h added after an incubation period of 18 h with CoCl2, just before completing the incubation period of 22 h). They were exposed to a source of 60Co in a dose range between 2 and 10 Gy to obtain survival curves that are fitted to a mathematical model. CoCl2 or chetomin treatments do not affect the viability of LNCaP cells that remained unchanged after irradiation. CoCl2 induced hypoxia reduces the survivability of LNCaP, and obstruction of HIF-1α signaling with chetomine produces a slight radioprotective effect. As others report, the genetic reprogramming induced by HIF-1α activation acts as an intrinsic agent that selects cells with more aggressive behavior (Pressley et al., 2017), while chetomin protects cells from death due to its scavenger properties. Interestingly, treatment with chetomin of cells induced to hypoxia (HIF-1 activation with CoCl2) produces a significant reduction in the radioresistance of LNCaP cells, demonstrating that the simultaneous use of chetomin and gamma radiation is an effective option for the treatment of hypoxic prostate cancer. At the molecular level, we suggest that the selective force exerted by HIF-1α depends on the production of free radicals by radiation. The proposed mathematical model showed that the rate of change in cell survival as a function of radiation dose is proportional to the product of two functions, one that describes cell death and the other that describes natural or artificial resistance to radiation.


Subject(s)
Hypoxia-Inducible Factor 1, alpha Subunit , Prostatic Neoplasms , Signal Transduction , Cell Line, Tumor , Cell Survival , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/antagonists & inhibitors , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Male , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/radiotherapy , Tumor Hypoxia
2.
Ann Hematol ; 99(8): 1701-1707, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-613171

ABSTRACT

COVID-19 pandemia is a major health emergency causing hundreds of deaths worldwide. The high reported morbidity has been related to hypoxia and inflammation leading to endothelial dysfunction and aberrant coagulation in small and large vessels. This review addresses some of the pathways leading to endothelial derangement, such as complement, HIF-1α, and ABL tyrosine kinases. This review also highlights potential targets for prevention and therapy of COVID-19-related organ damage and discusses the role of marketed drugs, such as eculizumab and imatinib, as suitable candidates for clinical trials.


Subject(s)
Betacoronavirus , Complement Inactivating Agents/administration & dosage , Coronavirus Infections/metabolism , Drug Delivery Systems/methods , Endothelium, Vascular/metabolism , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Pneumonia, Viral/metabolism , Protein-Tyrosine Kinases/metabolism , Antibodies, Monoclonal, Humanized/administration & dosage , COVID-19 , Clinical Trials, Phase II as Topic/methods , Coronavirus Infections/drug therapy , Coronavirus Infections/pathology , Endothelium, Vascular/drug effects , Endothelium, Vascular/pathology , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/antagonists & inhibitors , Imatinib Mesylate/administration & dosage , Pandemics/prevention & control , Pneumonia, Viral/drug therapy , Pneumonia, Viral/pathology , Protein-Tyrosine Kinases/antagonists & inhibitors , SARS-CoV-2 , Signal Transduction/drug effects , Signal Transduction/physiology
SELECTION OF CITATIONS
SEARCH DETAIL